BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16529031)

  • 1. [Pharmacogenomics in chemotherapy and drug development for breast cancer].
    Shimizu C; Fujiwara Y
    Nihon Rinsho; 2006 Mar; 64(3):424-31. PubMed ID: 16529031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
    Brenton JD; Carey LA; Ahmed AA; Caldas C
    J Clin Oncol; 2005 Oct; 23(29):7350-60. PubMed ID: 16145060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in breast cancer: current trends and future directions.
    Wajapeyee N; Somasundaram K
    Curr Opin Mol Ther; 2004 Jun; 6(3):296-301. PubMed ID: 15264432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
    Kaklamani V
    Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
    Pusztai L; Rouzier R; Wagner P; Symmans WF
    Drug Resist Updat; 2004 Dec; 7(6):325-31. PubMed ID: 15790543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized systemic treatment for breast cancer patients: is it a reality?
    Shimizu C; Fujiwara Y
    Breast Cancer; 2008; 15(2):141-4. PubMed ID: 18274835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
    Ansari M; Krajinovic M
    Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics and -genetics in colorectal cancer.
    Pohl A; Lurje G; Manegold PC; Lenz HJ
    Adv Drug Deliv Rev; 2009 May; 61(5):375-80. PubMed ID: 19100300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.
    Marsh S; Liu G
    Adv Drug Deliv Rev; 2009 May; 61(5):381-7. PubMed ID: 19100797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles of the oestrogen receptor in breast cancer.
    Kok M; Linn SC
    Neth J Med; 2010 Oct; 68(10):291-302. PubMed ID: 21071774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
    Lee W; Lockhart AC; Kim RB; Rothenberg ML
    Oncologist; 2005 Feb; 10(2):104-11. PubMed ID: 15709212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of breast cancer: toward the individualization of therapy.
    Chang JC; Hilsenbeck SG; Fuqua SA
    Cancer Invest; 2009 Aug; 27(7):699-703. PubMed ID: 19637041
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach.
    Vera-Ramirez L; Sanchez-Rovira P; Ramirez-Tortosa CL; Quiles JL; Ramirez-Tortosa MC; Alvarez JC; Fernandez-Navarro M; Lorente JA
    Cancer Treat Rev; 2010 Oct; 36(6):477-84. PubMed ID: 20299155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer.
    Chow LW
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S13-7. PubMed ID: 20374025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
    Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
    Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.